Efficacy and safety of recombinant human thrombopoietin combined with different doses of glucocorticoid on patients with thrombocytopenia
10.3969/J.ISSN.1672-8270.2015.07.025
- VernacularTitle:重组人血小板生成素联合不同剂量糖皮质激素治疗血小板减少症的疗效和安全性研究
- Author:
Li CHEN
- Publication Type:Journal Article
- Keywords:
Thrombocytopenia;
Recombinant human thrombopoietin;
Glucocorticoid
- From:
China Medical Equipment
2015;(7):75-77,78
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the efficacy and safety of recombinant human thrombopoietin combined with different doses of glucocorticoid on patients with thrombocytopenia.Methods: Choose patients with thrombocytopenia in our hospital as research subjects, randomly divided into control group with recombinant human thrombopoietin and normal glucocorticoid, observation group with recombinant human thrombopoietin and reduction glucocorticoid, compared platelet levels, onset time, coagulation and adverse reactions.Results: 1)observation group patients platelet levels after treatment was significantly higher than control group patients (t=5.931,t=6.273;P<0.05); 2)observation group patients average rise time of platelet were significantly less than control group patients (t=4.284,t=6.294, t=6.482;P<0.05); 3)observation group patients PT, APTT values were lower than control group, FIB level was higher (t=5.392,t=6.183,t=7.273;P<0.05); 4)patients in the observation group incidence of various types of adverse reactions after treatment was significantly lower than control group patients(x2=7.017,x2=4.833,x2=5.199,x2=4.921;P<0.05).Conclusion: The recombinant human thrombopoietin joint reduction of glucocorticoid therapy can improve platelet levels in patients with thrombocytopenia, improve coagulation and rapid onset of adverse reactions , with positive clinical significance.
